Elraglusib

The FDA granted orphan drug designation to elraglusib, a GSK-3β inhibitor, for treating soft tissue sarcoma. Elraglusib shows promise in addressing unmet medical needs in advanced cancers, with a favorable safety profile and antitumor activity. It's under study in a phase 2 trial for sarcomas and in phase 1 for solid tumors and hematologic malignancies, demonstrating potential in combination therapies and monotherapy.

Elraglusib, a novel GSK-3β inhibitor by Actuate Therapeutics, received FDA Orphan Drug Designation for treating soft tissue sarcoma, highlighting its potential in addressing unmet medical needs in cancer treatment. It shows promise in inducing cancer cell apoptosis and synergizing with chemotherapy, offering hope for patients with metastatic STS.

Actuate Therapeutics received FDA orphan-drug designation for elraglusib, targeting rare soft tissue sarcomas. The designation offers extended marketing exclusivity. Elraglusib has shown promising safety and antitumor activity in various cancers, including melanoma and pancreatic cancer.

Actuate Therapeutics reports elraglusib shows anti-tumor activity with 2 durable complete responses and ~62% disease control rate in 8 relapsed/refractory Ewing and Ewing-related sarcoma patients. Enrollment continues with topline data expected in 1H 2025.

Actuate Therapeutics updates on Phase 1/2 trial of elraglusib for relapsed/refractory Ewing Sarcoma, showing promise with early clinical data. Two patients achieved complete responses, and one with Desmoplastic Small-Round-Cell Tumor had a 52% tumor reduction. The study continues, aiming to enroll up to 12 EWS patients for further development.

Elraglusib, an investigational GSK-3β inhibitor, received FDA orphan drug designation for pancreatic cancer treatment. It's being tested in phase 1/2 and phase 2 trials, combined with various therapies, for advanced and metastatic pancreatic cancer, aiming to address the high unmet medical need with less than 10% 5-year survival rate.

The FDA granted orphan drug designation to elraglusib for pancreatic cancer treatment. Actuate Therapeutics is exploring its safety and efficacy in phase 1/2 trials, including combinations with chemotherapy. Elraglusib targets GSK-3β, showing antitumor activity by inhibiting cancer growth. Ongoing trials aim to advance its development for pancreatic cancer patients.

Actuate Therapeutics received FDA Orphan Drug Designation for elraglusib, targeting pancreatic cancer, a disease with less than 10% 5-year survival in the US. Elraglusib, a GSK-3β inhibitor, is in phase 2 trials, including combinations with gemcitabine/nab-paclitaxel and FOLFIRINOX, aiming to address this high unmet medical need.